Results 141 to 150 of about 23,995,861 (305)

Mixed-effects modeling for teammate trustworthiness.

open access: yes, 2019
Mixed-effects modeling for teammate trustworthiness.
Ravi S. Kudesia (738850)   +1 more
core   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

LLM use during exam preparation and student performance in university mathematics: a quantitative observational study

open access: yesFrontiers in Education
The integration of large language models (LLMs) into student study practices raises important questions about their association with academic performance, yet empirical evidence from authentic university settings remains scarce.
Michaela Tichá, Jiří Přibyl
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Trend-resistant and cost-efficient cross-over designs for mixed models. [PDF]

open access: yes
A mixed model approach is used to construct optimal cross-over designs. In a cross-over experiment the same subject is tested at different points in time.
Tack, L, Vandebroek, Martina
core  

A bivariate mixed model approach for the analysis of plant survival data

open access: yes, 2013
Disease resistance is often measured as plant survival, which involves taking multiple counts of plants before and after disease incidence. Often, survival data are analyzed by forming a single derived variable, namely final counts expressed as a ...
Beeck, C.   +10 more
core   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Lack-of-fit tests in semiparametric mixed models. [PDF]

open access: yes
In this paper we obtain the asymptotic distribution of restricted likelihood ratio tests in mixed linear models with a fixed and finite number of random effects.
Claeskens, Gerda   +2 more
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy